Aradigm Appoints Timothy Lynch to Board of Directors

Aradigm Corporation (OTCBB:ARDM) today announced it appointed Timothy Lynch to its board of directors. Mr. Lynch served as the Chief Financial Officer of biopharmaceutical company Tercica and before that, InterMune. Prior to his CFO roles, Mr. Lynch worked at Elan Corporation as Director of Strategic Planning and in investment banking at Goldman Sachs. He holds degrees from Harvard Business School and Colgate University. Mr. Lynch also serves on the board of directors of Allos Therapeutics, BioForm Medical and Nabi Biopharmaceuticals. "We are delighted that Tim Lynch is joining our board. He has an impressive track record of achievements with emerging specialty pharmaceutical companies, and his experience as a senior finance and business executive will be particularly valuable to Aradigm at this stage of the Company’s development,” said Virgil Thompson, Aradigm’s Chairman of the Board. "I would like to use this opportunity also to thank our board member Stephen Jaeger for his contributions to Aradigm Corporation. Due to the demands of his other professional responsibilities, Stephen has reluctantly decided to not stand for re-election to Aradigm’s board in 2008.” Mr. Jaeger’s term on Aradigm’s board runs through the Company’s annual shareholder meeting in mid-May 2008. About Aradigm Aradigm is an emerging specialty pharmaceutical company focused on the development and commercialization of a portfolio of drugs delivered by inhalation for the treatment and prevention of severe respiratory diseases by pulmonologists. Current activities include partnered and self-initiated development programs addressing the treatment of cystic fibrosis, bronchiectasis, pulmonary hypertension, inhalation anthrax infections and smoking cessation. In addition, Aradigm’s AERx® insulin Diabetes Management System (iDMS), which has been licensed to Novo Nordisk for development and commercialization in return for royalties, is in Phase 3 testing for Type 1 and Type 2 diabetes. Under the agreements with Novo Nordisk, Novo Nordisk is responsible for all further clinical, manufacturing and commercial development, while Aradigm and Novo Nordisk continue to cooperate and share in technology development, as well as intellectual property development and defense. More information about Aradigm can be found at www.aradigm.com. Aradigm and AERx are registered trademarks and the Aradigm Logo is a trademark of Aradigm Corporation.